News and Trends 21 Sep 2015
Shire’s Adderall alternative granted EMA approval for EU
Intuniv, Shire‘s new anti-stimulatory product for children with attention-deficit hyperactivity disorder (ADHD) between 6-17 years old, is set to hit shelves in Europe following successful market approval by the European medicine agency (EMA). Shire, a pharma giant with a €23.5Bn market cap, dominates the ADHD market. Originally from Basingstoke (England), they also have bases in the […]
